2. Search Result
Search Result
Results for "

Medullary

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

1

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99160
    Labetuzumab

    hMN14

    		 Transmembrane Glycoprotein Cancer
    Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
    Labetuzumab
  • HY-W009776
    Suberoyl bis-hydroxamic acid

    Suberohydroxamic acid; SBHA

    		 HDAC Apoptosis Cancer
    Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID50 values of 0.25 μM and 0.30 μM, respectively .Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways .Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC) .
    Suberoyl bis-hydroxamic acid
  • HY-B1096
    Etamivan

    Ethamivan; N,N-Diethylvanillamide

    		 Biochemical Assay Reagents Neurological Disease
    Etamivan (Ethamivan; N,N-Diethylvanillamide) is an orally active respiratory stimulant. Ethamivan regulates breathing patterns by directly stimulating the medullary respiratory center, prioritizing increased breathing depth rather than frequency. Etamivan can be used in the research of barbiturate overdose and chronic obstructive pulmonary disease .
    Etamivan
  • HY-156135
    NSC194598

    		MDM-2/p53 RET DNA/RNA Synthesis Apoptosis Caspase Endocrinology Cancer
    NSC194598 is a p53 DNA-binding inhibitor with an IC50 value of 180 nM. NSC194598 inhibits p53 DNA binding and induction of target genesn when p53 is stabilized and activated by irradiation or chemotherapy. NSC194598 can interfere with transcriptional activation of mutated rearranged during transfection (RET) gene, induce apoptosis and G0/G1 phase arrest. NSC194598 can be used for the researches of acute radiation toxicity and medullary thyroid carcinoma .
    NSC194598
  • HY-101246
    RPI-1

    		RET Cancer
    RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .
    RPI-1
  • HY-108585A
    VU591

    		Potassium Channel Neurological Disease
    VU591 is a potent, selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor, with an IC50 of 0.24 μM. VU591 can be used for neurological research with HY-108585 (the equivalent of VU591 hydrochloride) .
    VU591
  • HY-108595
    VU590
    2 Publications Verification

    		 Potassium Channel Others
    VU590 is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC50 of 290 nM. VU590 also inhibits Kir7.1, with an IC50 of 8 μM. VU590 is not a good probe of ROMK function in the kidney .
    VU590
  • HY-12143
    Vofopitant dihydrochloride

    GR 205171A

    		 Neurokinin Receptor Neurological Disease
    Vofopitant dihydrochloride (GR 205171A) is a blood-brain barrier-permeable NK1 receptor inhibitor with a pKi of 9.02 in mice. Vofopitant dihydrochloride blocks vomiting-related responses and inhibits pseudoptyalism. Vofopitant dihydrochloride exerts anxiolytic effects, regulates 5-HT receptor function and increases central 5-HT release. Vofopitant dihydrochloride improves hyperarousal symptoms of post-traumatic stress disorder. Vofopitant dihydrochloride can be used in research related to depression, anxiety, vomiting and postoperative nausea and vomiting .
    Vofopitant dihydrochloride
  • HY-108585
    VU591 hydrochloride

    		Potassium Channel Neurological Disease
    VU591 hydrochloride is a potent, selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor, with an IC50 of 0.24 μM. VU591 hydrochloride can be used for neurological research with HY-108585A (the equivalent of VU591 hydrochloride) .
    VU591 hydrochloride
  • HY-132201
    MK-8153

    		Potassium Channel Metabolic Disease
    MK-8153 is a potent, selective and orally active inhibitor of renal outer medullary potassium channel (ROMK), with IC50s of 5 nM, 34 μM for ROMK electrophysiology (EP) and hERG EP, respectively. MK-8153 can be used as the diuretic/atriuretic .
    MK-8153
  • HY-B1096R
    Etamivan (Standard)

    Ethamivan (Standard); N,N-Diethylvanillamide (Standard)

    		 Biochemical Assay Reagents Reference Standards Neurological Disease
    Etamivan (Ethamivan; N,N-Diethylvanillamide) (Standard) is the analytical standard of Etamivan (HY-B1096). This product is intended for research and analytical applications. Etamivan is an orally active respiratory stimulant. Ethamivan regulates breathing patterns by directly stimulating the medullary respiratory center, prioritizing increased breathing depth rather than frequency. Etamivan can be used in the research of barbiturate overdose and chronic obstructive pulmonary disease.
    Etamivan (Standard)
  • HY-121667
    Scaff10-8
    1 Publications Verification

    		 ROCK Cancer
    Scaff10-8, bound to RhoA, inhibits the AKAP-Lbc-mediated RhoA activation .
    Scaff10-8
  • HY-124944
    APS6-45

    		Ras Cancer
    APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity .
    APS6-45
  • HY-156113
    RET-IN-25

    		RET Cancer
    RET-IN-25 (compound 6b) is a RET kinase inhibitor with anticancer activity. RET-IN-25 inhibits medullary thyroid carcinoma (MTC) with IC50s of 3.6 μM (3 days) and 3.0 μM (6 days) against TT(C634R) MTC .
    RET-IN-25
  • HY-143546
    RET-IN-9

    		RET Cancer
    RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, and the maintenance of homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 has the potential for the research of RET-related disease including non-small cell lung cancer and medullary thyroid cancer (extracted from patent WO2021115457A1, compound 29) .
    RET-IN-9
  • HY-P1403
    Tertiapin LQ

    		Potassium Channel Others
    Tertiapin LQ is a specific and reversible renal outer medullary potassium ROMK1 (Kir1.1) channel inhibitor .
    Tertiapin LQ
  • HY-Y1876
    Guaiacol Carbonate

    		Drug Derivative Others
    Guaiacol Carbonate acts as an expectorant by virtue of a reflex from the stomach by way of the afferent gastric nerves to the medullary centres and thenperipherally again to the respiratory tract .
    Guaiacol Carbonate
  • HY-124687
    ROMK-IN-32

    		Potassium Channel Cardiovascular Disease
    ROMK-IN-32 is a renal outer medullary potassium channel (ROMK) inhibitor with an IC50 of 35 nM. ROMK-IN-32 also inhibits hERG with an IC50 of 22 μM .
    ROMK-IN-32
  • HY-162555
    BMS-986308

    		Potassium Channel Cardiovascular Disease
    BMS-986308 is a selective and orally active renal outer medullary potassium (ROMK) channel inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research .
    BMS-986308
  • HY-123803
    PF-06807656

    		Potassium Channel Cardiovascular Disease
    PF-06807656 is a selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor. PF-06807656 has an IC50 of 61 nM against hROMK in patch-clamp assays. PF-06807656 exhibits high selectivity for inhibiting rat ROMK and is insensitive to N171D pore mutations. PF-06807656 may be used in cardiovascular disease research .
    PF-06807656
  • HY-122282
    AZ11657312

    		Angiotensin Receptor Cardiovascular Disease
    AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure .
    AZ11657312
  • HY-170019
    RET-IN-28

    		RET Cancer
    RET-IN-28 (Compound 16) is a RET (transmembrane receptor tyrosine protein kinase) inhibitor. RET-IN-28 inhibits the activity of the mutant RET enzyme (RET-V804M), and can be applied to cancer research .
    RET-IN-28
  • HY-110076
    VU590 dihydrochloride

    		Potassium Channel Others
    VU590 dihydrochloride is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC50 of 290 nM. VU590 also inhibits Kir7.1, with an IC50 of 8 μM. VU590 dihydrochloride is not a good probe of ROMK function in the kidney .
    VU590 dihydrochloride
  • HY-183729
    RET-IN-34

    		Ligands for Target Protein for PROTAC RET Endocrinology Cancer
    RET-IN-34 (Compound EV1) is a RET inhibitor with an IC50 of 0.89 nM. RET-IN-34 serves as a target protein ligand for PROTAC synthesis (Ligand for Target Protein for PROTAC). RET-IN-34 is applicable for the synthesis of PROTAC RET Degrader 2 (HY-183783). RET-IN-34 exhibits anticancer activity against medullary thyroid carcinoma. RET-IN-34 can be used in studies related to medullary thyroid carcinoma .
    RET-IN-34
  • HY-183783
    PROTAC RET Degrader 2

    		PROTACs RET STAT ERK Apoptosis Endocrinology Cancer
    PROTAC RET Degrader 2 is a RET degrader with a target IC50 of 0.36 nM. PROTAC RET Degrader 2 is mainly composed of RET-IN-34 (HY-183729) and Thalidomide (HY-14658). PROTAC RET Degrader 2 mediates RET degradation via the ubiquitin-proteasome system. PROTAC RET Degrader 2 induces apoptosis, inhibits colony-forming ability, and exhibits antiproliferative activity in cancer cells. PROTAC RET Degrader 2 suppresses tumor growth in xenograft models. PROTAC RET Degrader 2 can be used in research related to medullary thyroid carcinoma, papillary thyroid carcinoma, and RET fusion-positive lung adenocarcinoma .
    PROTAC RET Degrader 2
  • HY-168880
    ROMK-IN-2

    		Potassium Channel Cardiovascular Disease
    ROMK-IN-2 (compond 1) is a potent renal outer medullary potassium (ROMK) inhibitor .
    ROMK-IN-2
  • HY-182377
    DT-5461

    		Interleukin Related TNF Receptor Inflammation/Immunology Cancer
    DT-5461 is an IL-1 and TNF-α antagonist. DT-5461 competitively binds lipid A-binding sites on macrophage receptors, blocks LPS (HY-D1056)-initiated signaling, inhibits LPS-induced cytokine release, prevents LPS-induced serum cytokine production in mice, and protects against LPS-induced lethal endotoxemia. DT-5461 can be used for the research of lethal endotoxemia, medullary tubular mammary carcinoma, poorly differentiated colon adenocarcinoma, squamous-cell lung carcinoma, and gelatinous gastric adenocarcinoma .
    DT-5461
  • HY-183684
    RET-IN-33

    		RET VEGFR PDGFR Akt ERK Endocrinology Cancer
    RET-IN-33 (Compound CN-3) is a moderately selective inhibitor of RET mutants. RET-IN-33 potently inhibits G810 mutants, with IC50 values of 4.43 nM (G810R), 3.28 nM (G810C) and 0.51 nM (G810S), respectively. RET-IN-33 also inhibits other RET mutants: V804M (IC50 0.73 nM), V804L (IC50 0.36 nM), Y806H (IC50 0.74 nM) and M918T (IC50 0.55 nM). RET-IN-33 also inhibits other kinases, with an IC50 of 1.50 nM against VEGFR2 and 1.60 nM against PDGFRα. RET-IN-33 blocks the autophosphorylation of RET mutants and the downstream SHC/AKT/ERK signaling pathway. RET-IN-33 selectively inhibits the proliferation of RET-driven cell models without affecting non-RET-dependent or normal cells. RET-IN-33 exhibits dose-dependent antitumor efficacy in RET-driven xenograft models. RET-IN-33 can be used for the research of medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer .
    RET-IN-33
  • HY-108595R
    VU590 (Standard)

    		Reference Standards Potassium Channel Others
    VU590 (Standard) is the analytical standard of VU590 (HY-108595). This product is intended for research and analytical applications. VU590 is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC50 of 290 nM. VU590 also inhibits Kir7.1, with an IC50 of 8 μM. VU590 is not a good probe of ROMK function in the Kidney .
    VU590 (Standard)
  • HY-180401
    DMP 811

    		Angiotensin Receptor Cardiovascular Disease
    DMP 811 is a potent, orally active and selective angiotensin II subtype receptor AT1 antagonist. DMP 811 exhibits selectivity for AT1 (IC50 = 6 nM) over AT2 (IC50 >10 μM). DMP 811 exhibits potent antihypertensive activity in rats and dogs. DMP 811 can be used for the research of hypertension .
    DMP 811

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: